Telephone follow-up does not reduce rehospitalization for low-risk heart failure patients

October 18, 2004

STANFORD, Calif. - Nurse care management - a widely used system of telephone-based health instruction and follow-up designed to help patients manage their illnesses - did not lower rehospitalization rates in clinically low-risk heart failure patients, according to a new study by researchers at the Stanford University School of Medicine.

The findings, which appear in the Oct. 19 issue of Annals of Internal Medicine, are at odds with past studies that show substantial benefits to specialized care management. The authors suggest that nurse care management does not measurably improve the health of clinically low-risk heart failure patients who, like the ones in this study, are receiving comprehensive health care.

"Nurse care management holds tremendous promise for patients at higher risk or those not receiving comprehensive care, but that doesn't mean it's universally effective," said Robert F. DeBusk, MD, professor of medicine (cardiovascular medicine) and lead author of the study.

Heart failure is the leading cause of hospitalization in people age 65 or older. It is a chronic ailment in which the heart loses some of its pumping capacity, though it may keep beating normally. It differs from heart attack, in which blood flow to the heart muscle itself is restricted.

DeBusk and his team studied 462 patients receiving treatment for heart failure at five Kaiser Permanente hospitals in the San Francisco Bay area. Half of the participants received nurse care management. Nurses at Stanford phoned these patients 16 times during the yearlong study to instruct them about their condition and check that they were taking the appropriate medications. All participants received the usual follow-up care provided by their own doctor.

"The idea is that if you give patients information on how to manage their illness, they will do it," said DeBusk. That's what previous studies of nurse care management conducted by DeBusk's team have shown.

But DeBusk's latest results reveal something different: half of the patients were rehospitalized, whether they received nurse care management or not. Only one-third of rehospitalizations were for treatment of heart failure; the majority was for treatment of coronary artery disease.

DeBusk, founder and director of the Stanford Cardiac Rehabilitation Program, offered two likely reasons why these findings depart from past work: differences in patients' baseline risk and differences in overall health care they received.

Other investigators evaluated patients with more advanced heart failure. As many as 90 percent of these patients were rated Class 3 or 4 - the two highest risk levels - on the New York Heart Association severity scale. Many had been hospitalized multiple times for heart failure. In contrast, only half of the patients in DeBusk's most recent study was rated as Class 3 or 4 and only 61 percent had been hospitalized previously for heart failure.

But DeBusk believes a second, more important reason is that his study enrolled patients who were already receiving good overall care from the Kaiser Permanente Medical Care Program. More than 90 percent of Kaiser patients in both study samples received medications recommended by national guidelines.

"We were dealing with a ceiling effect," said DeBusk. "It's hard to improve on excellent care."

He added, "The lesson is that nurse care management works best for high-risk patients."

DeBusk noted that there continues to be good reason for insurers to support nurse care management, especially for older patients, those with more severe symptoms or patients with inadequate social support.

The Stanford-Kaiser collaboration was novel. DeBusk's team of nurse care managers worked directly with Kaiser physicians, by telephone, to coordinate follow-up care in each of the participating hospitals. That makes the study's results more applicable to real-world health care, said DeBusk.

The Stanford Cardiac Rehabilitation Program has collaborated with Kaiser Permanente for more than 20 years. DeBusk said it had been a fruitful relationship. "We jointly developed the basis for this program, which was adopted by Kaiser Permanente and is still operational today," he said.
-end-
PRINT MEDIA CONTACT: Mitzi Baker at 650-725-2106 (mitzibaker@stanford.edu)
BROADCAST MEDIA CONTACT: M.A. Malone at 650-723-6912 (mamalone@stanford.edu)

Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.

Stanford University Medical Center

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.